Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes

Next Previous
Trial Profile

MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MER 3101 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 19 Nov 2019 Planned initiation date changed from 1 Jan 2019 to 1 Jan 2020.
    • 19 Nov 2019 Status changed from recruiting to not yet recruiting.
    • 15 Oct 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 4 Sep 2018 to 4 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top